Plus Therapeutics, Inc. receives FDA Orphan Drug Designation for its Novel Glioblastoma Treatment (GlobeNewswire) - Sep 1, 2020 - "Plus Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for its lead investigational drug, Rhenium NanoLiposomes (RNL™) for the treatment of patients with recurrent glioblastoma...Last week, the trials' Data Safety and Monitoring Board approved the Company to proceed to Cohort 6 which includes increasing both the drug volume and radiation dose to 8.8 milliliters (mL) and 22.3 millicuries (mCi), respectively."
Orphan drug • Trial status • Brain Cancer • Glioblastoma • Oncology
|